Trial Information
Program for Assessment of Capecitabine (Xeloda) Plus Docetaxel First-line Therapies in HER2-negative Metastatic Breast Cancer (XEBRA Study)
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- HER2-negative metastatic breast cancer
- Patients initiated on first-line therapy with Xeloda and docetaxel in accordance with
the Summary of Product Characteristics; patients who started treatment with Xeloda
and docetaxel no more than 3 months before enrollment in this study are also eligible
Exclusion Criteria:
- Contraindications to Xeloda treatment according to the Summary of Product
Characteristics
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Progression-free survival, defined as time from enrollment until disease progression or death of any cause
Outcome Time Frame:
approximately 3 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Hungary: National Institute of Pharmacy
Study ID:
ML28505
NCT ID:
NCT01777945
Start Date:
December 2012
Completion Date:
July 2015
Related Keywords:
- Breast Cancer
- Breast Neoplasms